Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 4/20 | 0.43 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | LDHA | P00338 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3779844 | 0.85 | TRPA1 (0.39) | MMECTSSCTSKLDHA | |
| SCHEMBL3775578 | 0.85 | CYP3A4 (0.40) | MMEACACBLMNAMEN1KMT2A | |
| SCHEMBL1867578 | 0.82 | ACACB (0.49) | MMEACACBEPHX1MEN1KMT2A | |
| SCHEMBL533999 | 0.81 | EPHX2 (0.39) | ACACBRAB9AMAOB | |
| SCHEMBL3785349 | 0.81 | EPHX2 (0.39) | LMNAEPHX1MEN1KMT2A | |
| SCHEMBL3776009 | 0.80 | PSIP1 (0.41) | MEN1KMT2A | |
| SCHEMBL27801725 | 0.74 | MME (0.43) | MMEACACBEPHX1MEN1KMT2A | |
| SCHEMBL2574724 | 0.74 | GCGR (0.41) | LMNA | |
| SCHEMBL2426124 | 0.72 | MMP8 (0.54) | MMEACACBLMNAMEN1KMT2A | |
| SCHEMBL9317096 | 0.72 | LDHA (0.52) | ACACBLMNAEPHX1KMT2ALDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394830-B2 | Quinolines and their therapeutic use | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2013-03-12 | — | — | US | disclosed |
| US-20120184579-A1 | Quinolines and Their Therapeutic Use | GB005, INC. | 2012-07-19 | — | — | US | disclosed |
| US-8173812-B2 | Quinolines and their therapeutic use | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2012-05-08 | — | — | US | disclosed |
| EP-2139881-B1 | QUINOLINES AND THEIR THERAPEUTIC USE | PULMAGEN THERAPEUTICS ASTHMA LTD (GB) | 2011-11-09 | — | — | EP | disclosed |
| US-20100144787-A1 | Quinolines and Their Therapeutic Use | GB005, INC. | 2010-06-10 | — | — | US | disclosed |
| EP-2139881-A1 | QUINOLINES AND THEIR THERAPEUTIC USE | Argenta Oral Therapeutics Limited (GB) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008122784-A1 | QUINOLINES AND THEIR THERAPEUTIC USE | ARGENTA DISCOVERY LIMITED (GB) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144787-A1 | Quinolines and Their Therapeutic Use | CHRM3, CHRM2, HRH1 | MME 4593/4885ACACB 3342/4885LMNA 3909/4885 |
| US-20120184579-A1 | Quinolines and Their Therapeutic Use | HRH1, CHRM2, CHRM3 | MME 4616/4885ACACB 3604/4885LMNA 4100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.